Anvisa approves registration of first gene therapy product for Duchenne Muscular Dystrophy (DMD)

News Healthcare & Pharma General Updates

Date: 2nd Dec, 2024 Source: National Health Surveillance Agency (Anvisa) Country: Brazil Original Source

Brief

On 02/12/2024, the National Health Surveillance Agency (Anvisa) issued an update regarding Anvisa approves registration of first gene therapy product for Duchenne Muscular Dystrophy (DMD). The Elevidys, a delandistrogeno moxeparvoveque, was approved for use in children aged 4-7 years with the disease, marking the first gene therapy approval in Brazil for this condition.

This content is restricted.

Highlights content goes here...

This content is restricted.

National Health Surveillance Agency (Anvisa)

RADA.AI

Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?

Suggested

Anvisa approves registration of first gene therapy product for Duchenne Muscular Dystrophy (DMD)

Brief

National Health Surveillance Agency (Anvisa)

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.

Anvisa approves registration of first gene therapy product for Duchenne Muscular Dystrophy (DMD)

Brief

National Health Surveillance Agency (Anvisa)

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify OTP

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.